Scholar Rock Holding Corporation
Financials
Valuation Metrics
Scholar Rock Holding Corporation's Market Cap is $5.59B. At end of 2025 it was $5.05B. Ranked #1242 of 3,121 in US market (top 40%), #416 of 1,463 on NASDAQ (top 28%), #70 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.59B | US#1,242/3,121 Sec#70/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-409M | US—/3,121 Sec—/266 |
| Total Assets | $524M | US#2,750/3,121 Sec#160/266 |
| Net Assets | $254M | US#2,594/3,121 Sec#169/266 |
| Employees | 289 | US#2,429/3,121 Sec#114/266 |
| Value | ||
| P/B | 22.03x | US#2,817/3,121 Sec#222/266 |
| FCF Yield | -5.30% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -161.00% | US#2,831/3,121 Sec#214/266 |
| ROA | -78.04% | US#3,043/3,121 Sec#245/266 |
| Financial Health | ||
| Debt Ratio | 106.29% | US#1,155/3,121 Sec#168/266 |
| Total Debt | $204M | US#2,247/3,121 Sec#95/266 |
| FCF | $-296M | US#2,845/3,121 Sec#230/266 |
| Cash | $437M | US#1,159/3,121 Sec#62/266 |
| Current Ratio | 7.02x | US#355/3,121 Sec#110/266 |
| Performance | ||
| 1Y Return | 43.63% | US#535/3,121 Sec#105/266 |
| 1M Return | -17.45% | US#2,478/3,121 Sec#191/266 |
| From 52W High | -24.47% | US#1,545/3,121 Sec#111/266 |
| 1Y MDD | -31.89% | US#1,547/3,121 Sec#99/266 |
| Trading | ||
| Volume | 3,029,349 shares | US#513/3,121 Sec#44/266 |
| Trading Value | $142M | US#552/3,121 Sec#35/266 |
| Per Share | ||
| EPS | $-3.41 | US—/3,121 Sec—/266 |
| BPS | $2.12 | US#2,567/3,121 Sec#179/266 |
Company Info
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.